| Name | Title | Contact Details |
|---|
Amyloid diseases are a diverse group of disorders, characterized by the deposition of amyloid protein fibrils in vital organs and tissues. There are approximately 30 different types of amyloidosis, each resulting from the misfolding and aggregation of a specific protein, and they are all severely debilitating, progressive, and often fatal.
HudsonAlpha Institute seeks to expand the science of human genomics and hasten its movement into the marketplace where discoveries can benefit society.
Nemus Bioscience Inc. is a biopharmaceutical company focused on discovering, developing and commercializing new chemical entities from a class of chemically diverse compounds called cannabinoids, designed to alleviate a variety of diseases and symptoms by selectively targeting CB1 and CB2 receptors. NEMUS Bioscience Inc. is developing a novel and proprietary class of product candidates that are designed to target the body`s nervous and immune systems without inducing many of the undesirable side effects typically associated with currently available therapeutics. NEMUS Bioscience Inc., a Nevada corporation is listed on the OTC Bulletin Board and trading under the symbol NMUS. To become a leading developer of cannabis-based therapeutics to address unmet medical needs on a global basis.
Tioma is an immuno-oncology company developing anti-CD47 antibodies for the treatment of solid and hematologic cancers. Our functionally diverse antibodies represent a new class of checkpoint inhibitors that harness both the adaptive and innate immune responses.
Mateon Therapeutics/Oncotelic is developing TGF-beta therapies and Apomorphine for Parkinson, ED, FSD. https://t.co/nReUVgPvhc. $OTLC